Patented drug launches help MNCs score over Indian peers

Source: The Economic Times, Sept 12, 2017

MUMBAI: At a time when the pharmaceuticals industry is facing the heat with price cuts and regulatory issues in the country, multinational companies are growing faster than their domestic peers due to better product mix, says a study.

While Indian companies still control almost 80% of the Rs 1 lakh crore pharma market in the country, the strategy of launching specialised patented product is helping multinationals grow much faster in India, a report released by market research firm AWACS has said.

While the overall Indian pharma companies registered 1.4% year-on-year growth in August, MNCs clocked 6.2% growth during the month, led by companies such as AstraZeneca, Janssen and Boehringer Ingelheim on the back of their brands Glycomet, Invokana, and Jardiance, respectively, the study said. Read the rest of this entry »


Govt’s proposed pharma marketing rules hit legal roadblock

Source:, Aug 24, 2017

Mumbai: India’s plan to bring in marketing rules to curb unethical promotional practices in the country’s drug industry faces an indefinite delay after it hit a legal roadblock, marking a setback for public health groups.

The country’s law ministry has rejected draft marketing rules, which were prepared by the Department of Pharmaceuticals (DoP) after nearly two years of deliberations, saying they cannot be passed under the proposed legal framework, industry sources told Reuters.

DoP officials did not respond to requests for comment, and G.N. Raju, secretary at the law ministry’s legislative department declined to comment beyond saying that the ministry had responded to the DoP on the draft weeks ago.

Read the rest of this entry »

Govt plans bulk drugs parks, import curbs to boost manufacturing in India

Source:, Aug 21, 2017

New Delhi: In a bid to revive India’s active pharmaceutical ingredient (API) and bulk drug market, the government is contemplating restrictions on the import of APIs and has suggested setting up of mega bulk drug parks, a move that is expected to boost domestic production.

In the draft pharmaceutical policy framed by the department of pharmaceuticals under the ministry of chemicals and fertilizers, the centre has proposed “peak customs duty” for all APIs that can be indigenously manufactured.

Bulk drugs or APIs are the active raw materials used in a drug that give it the therapeutic effect. “All APIs which can be indigenously manufactured should be imported at peak customs duty,” said the draft policy, reviewed by Mint.

Read the rest of this entry »

New pharma policy may fix drug trade margins

download (10).jpgSource: Business Standard, Aug 17, 2017

New Delhi: In an attempt to make drugs affordable to all, the government has planned a fresh pharmaceutical policy. The policy draft says that the government will fix trade margins for drugs as well. At present, the National Pharmaceutical Pricing Authority (NPPA) is in the process of fixing trade margins for a number of medical devices like orthopedic knee implants and cardiac stents.

According to the draft, which Business Standard reviewed, “The issue of unreasonable trade margins and bonus offers by various stockists, distributors and retailers has been adversely affecting both the industry as well as consumer interest. After detailed stakeholder consultations, the level of trade margins will be prescribed to create a level playing field for the industry and to bring down the prices.” It also states that institutions that procure directly from manufacturers will also be subject to this regulation.

Read the rest of this entry »

Indian pharma poised for US acquisitions

Source: Business Standard, Aug 08, 2017

Mumbai: The assets of Teva Pharmaceutical Industries have become acquisition targets following devastating results announced last week by the world’s biggest maker of generic medicines.

Teva’s profits in the second quarter dropped to $1 billion from $1.23 billion a year earlier. Its stock slumped the most in almost two decades and the yield on its bonds jumped after the drugmaker warned that it might breach some debt covenants this year if sales did not rise.

Read the rest of this entry »

Govt stops $1.3bn Chinese bid for Gland Pharma

download (2).jpgSource: Times of India, Aug 01, 2017

NEW DELHI: The Centre has stalled a $1.3-billion bid by Shanghai Fosun Pharmaceutical Group (SFP) to acquire an 86% stake in Hyderabad-based Gland Pharma, citing “genuine concerns” over proprietary technology developed by the Indian company going over to a Chinese pharma major.

Top government officials on Monday dismissed media reports that the decision was linked to the current border stand-off between the two countries.

Read the rest of this entry »

Indian pharma team heading to St Petersburg to explore jt ventures

Source: The Hindu Business Line, July 25, 2017

New Delhi: Responding to Russia’s call for collaboration in the pharmaceutical sector, India is planning to turn an exhibition for domestic drug producers in St Petersburg in September into a hunting ground for companies interested in joint ventures to tap the vast Russian market.

“We have asked the Pharmaceuticals Export Promotion Council of India (Pharmexcil) to identify companies interested in Russia and carry out a due diligence. Since there is already an exhibition planned for Indian drug companies in St Petersburg in September, if the due-diligence is done by that time, some of the companies interested in joint ventures can also travel with the delegation and explore possibilities,” a government official told BusinessLine.

Read the rest of this entry »